Summary
Surgify’s mission is to make bone surgery safer around the globe. Our product - Surgify Safety Burr (SSB) enables surgeons to cut bone safely, accurately and fast without compromising the safety of important soft structures. The core innovation is in the mechanisms of a disposable cutting tip of a surgical drill. SSB automatically covers the cutting edges of the small drill tip when it comes into contact with soft tissue.
Surgify has successfully tested the technology in preclinical setups with human and animal cadavers (TRL:6). Based on non-clinical trials by surgeons, Surgify estimates that SSB can realistically reduce the risk of soft tissue injuries with 80% - 91%. Academic research shows that patients without dural tears have 42% - 97% less complications. World-famous neurosurgeon, Professor Juha Hernesniemi has stated: “Breakthrough!”
The first target applications (est. potential €640M) are skull, spine and ear procedures, which account for 55% of the bone cutting disposable attachment market (€1.2B). In the future, Surgify can expand to other fields of surgery as well as robotic surgery applications.
Surgify has multiple ongoing pilots and signed letters of intent worth €355k / year. In September 2017, Surgify’s CEO received the prestigious MIT Technology Review Innovators Under 35 Europe award. In December 2018, Surgify was named as one of the 24 winners of the European Venture Contest, arranged by TechTour.
The SME Phase 1 funding is critical for Surgify. It will be used to further develop a focused, detailed and achievable commercial and operational business plan that adds necessary expertise and scales the sales and revenue delivery to deliver the 2021/2022 goals. With this funding, we can find commercial manufacturing partners, complete a detailed market analysis, interview leading surgeons and prepare necessary commercial plan with financial forecasts to raise SME Phase 2 and/or VC funding for commercial product launch by the end of 2019.
Surgify has successfully tested the technology in preclinical setups with human and animal cadavers (TRL:6). Based on non-clinical trials by surgeons, Surgify estimates that SSB can realistically reduce the risk of soft tissue injuries with 80% - 91%. Academic research shows that patients without dural tears have 42% - 97% less complications. World-famous neurosurgeon, Professor Juha Hernesniemi has stated: “Breakthrough!”
The first target applications (est. potential €640M) are skull, spine and ear procedures, which account for 55% of the bone cutting disposable attachment market (€1.2B). In the future, Surgify can expand to other fields of surgery as well as robotic surgery applications.
Surgify has multiple ongoing pilots and signed letters of intent worth €355k / year. In September 2017, Surgify’s CEO received the prestigious MIT Technology Review Innovators Under 35 Europe award. In December 2018, Surgify was named as one of the 24 winners of the European Venture Contest, arranged by TechTour.
The SME Phase 1 funding is critical for Surgify. It will be used to further develop a focused, detailed and achievable commercial and operational business plan that adds necessary expertise and scales the sales and revenue delivery to deliver the 2021/2022 goals. With this funding, we can find commercial manufacturing partners, complete a detailed market analysis, interview leading surgeons and prepare necessary commercial plan with financial forecasts to raise SME Phase 2 and/or VC funding for commercial product launch by the end of 2019.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/878204 |
| Start date: | 01-08-2019 |
| End date: | 31-01-2020 |
| Total budget - Public funding: | 71 429,00 Euro - 50 000,00 Euro |
Cordis data
Original description
Surgify’s mission is to make bone surgery safer around the globe. Our product - Surgify Safety Burr (SSB) enables surgeons to cut bone safely, accurately and fast without compromising the safety of important soft structures. The core innovation is in the mechanisms of a disposable cutting tip of a surgical drill. SSB automatically covers the cutting edges of the small drill tip when it comes into contact with soft tissue.Surgify has successfully tested the technology in preclinical setups with human and animal cadavers (TRL:6). Based on non-clinical trials by surgeons, Surgify estimates that SSB can realistically reduce the risk of soft tissue injuries with 80% - 91%. Academic research shows that patients without dural tears have 42% - 97% less complications. World-famous neurosurgeon, Professor Juha Hernesniemi has stated: “Breakthrough!”
The first target applications (est. potential €640M) are skull, spine and ear procedures, which account for 55% of the bone cutting disposable attachment market (€1.2B). In the future, Surgify can expand to other fields of surgery as well as robotic surgery applications.
Surgify has multiple ongoing pilots and signed letters of intent worth €355k / year. In September 2017, Surgify’s CEO received the prestigious MIT Technology Review Innovators Under 35 Europe award. In December 2018, Surgify was named as one of the 24 winners of the European Venture Contest, arranged by TechTour.
The SME Phase 1 funding is critical for Surgify. It will be used to further develop a focused, detailed and achievable commercial and operational business plan that adds necessary expertise and scales the sales and revenue delivery to deliver the 2021/2022 goals. With this funding, we can find commercial manufacturing partners, complete a detailed market analysis, interview leading surgeons and prepare necessary commercial plan with financial forecasts to raise SME Phase 2 and/or VC funding for commercial product launch by the end of 2019.
Status
CLOSEDCall topic
EIC-SMEInst-2018-2020Update Date
27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
